May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Bevacizumab, Intravitreal Treament for Exudative Macular Degeneration (AMD)
Author Affiliations & Notes
  • K.W. Small
    Molecular Insight LLC, Los Angeles, CA
    Ophthalmology, Cedars–Sinai Medical Center, Los Angeles, CA
  • R. Silva–Garcia
    Molecular Insight LLC, Los Angeles, CA
    Glendale Eye Medical Group, Glendale, CA
  • Footnotes
    Commercial Relationships  K.W. Small, None; R. Silva–Garcia, None.
  • Footnotes
    Support  unrestricted grant from Molecular Insight LLC
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5229. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K.W. Small, R. Silva–Garcia; Bevacizumab, Intravitreal Treament for Exudative Macular Degeneration (AMD) . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5229.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Preliminary reports of intravitreal BEVACIZUMAB (an anti–VEGF monoclonal antibody) suggested beneficial effects in a few cases of wet age–related macular degeneration (AMD). We wanted to review our clinical experience in a private practice setting with this new treatment because our clinical impression was favorable.

Methods: : Retrospective consecutive case review of 59 cases. Pre and post injection data that was reviewed consisted of best corrected visual acuity, macular thickness by OCT, fundus photography and fluorescein angiography (IVFA). Of the 59 cases, we have at least 2 month follow–up data on 50 cases.

Results: : No complications or adverse events were observed. The visual acuity improved by 0.77 lines on average (ranged from –2 to +8 lines). 49 of 50 were stable or improved (within 2 lines of baseline vision). 6 of 50 had improved by more than 3 lines of visual acuity. The OCT demonstrated on average 73 microns improvement in thickness (range 913–26 microns less thickening). 43 of the 50 subjects showed clinical and / or IVFA signs of improvement (i.e. less submacular fluid , blood or exudate).

Conclusions: : Intravitreal BEVACIZUMAB seems safe and well tolerated for at least 3 months following injection. Overall, subjects seemed to show a good response to intravitreal BEVACIZUMAB. Duration of exudative AMD and previous treatments correlated with poor visual outcomes. The cases that had the best outcomes were ones with relatively new (less than 3 months duration) choroidal neovascularization and which had not been previously treated with photodynamic therapy and / or Macugen. Although the follow–up is relatively brief, the rapid postive and sometimes dramatic responses seem superior to other current standard of care treaments. Six month follow – up data of these subjects will be analyzed and presented.

Keywords: age-related macular degeneration • choroid: neovascularization • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.